Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (118)

« Back to Publications

Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid.

Dunn S. et al, (2026), BMJ open, 16

Efficacy and Safety of Obexelimab to Treat IgG4-Related Disease: Protocol for a Global, Randomized, Placebo-Controlled Trial.

Culver EL. et al, (2026), Rheumatology and therapy

The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view.

Jones DEJ. et al, (2026), Nature reviews. Gastroenterology & hepatology

Pruritus is common in primary sclerosing cholangitis, persists over time, and its intensity is associated with disease severity: a multicentre, prospective observational study.

Hussain N. et al, (2025), Hepatology (Baltimore, Md.)

Adherence to United European Gastroenterology Guidelines on Diagnosis and Therapy of Immunoglobulin-G4-Related Digestive Disease.

Vujasinovic M. et al, (2025), United European gastroenterology journal, 13, 1583 - 1592

Enhancing Liver Fibrosis Measurement: Deep Learning and Uncertainty Analysis Across Multi-Centre Cohorts

Wojciechowska M. et al, (2025)

Inebilizumab for Treatment of IgG4-Related Disease.

Stone JH. et al, (2025), The New England journal of medicine, 392, 1168 - 1177

Exploring cardiovascular involvement in IgG4-related disease: a case series approach with cardiovascular magnetic resonance

Henry JA. et al, (2025), Heart, 111, 133 - 140

Dye-based chromoendoscopy detects more neoplasia than white light endoscopy in patients with primary sclerosing cholangitis and IBD.

Motta RV. et al, (2024), Endoscopy international open, 12, E1285 - E1294

Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?

Jones DEJ. et al, (2024), Hepatology (Baltimore, Md.), 80, 1291 - 1300

Prospective cohort for early detection of liver cancer (Pearl): a study protocol

Khanna K. et al, (2024), BMJ Open, 14, e085541 - e085541

Fibrotic phenotype of IgG4-related disease.

Lanzillotta M. et al, (2024), The Lancet. Rheumatology, 6, e469 - e480

Type 1 Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment.

Overbeek KA. et al, (2024), Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 22, 994 - 1004.e10

Challenges and pitfalls in the diagnosis of IgG4-related disease.

Bateman AC. and Culver EL., (2024), Seminars in diagnostic pathology, 41, 45 - 53

IgG4 autoantibodies and autoantigens in the context of IgG4-autoimmune disease and IgG4-related disease.

Motta RV. and Culver EL., (2024), Frontiers in immunology, 15

Load More

1
2
3
4
5
6
7
...
»